MedTrace Logo

COMPACT - COMbining Plasma-filtration and Adsorption Clinical Trial

NCT00332371 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2012-07-09

No results posted yet for this study

Summary

The study objective is to clarify whether the application of CPFA (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce mortality and prevent organ failures in septic shock patients in intensive care unit (ICU).

Conditions

  • Shock, Septic

Interventions

DEVICE

CPFA (Coupled Plasma Filtration Adsorption)

CPFA is a specific method for the treatment of sepsis. It consists of: 1. a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa) 2. a hemofilter (polyethersulfone 1,4 m2) 3. a cartridge (contains approximately 140 ml of hydrophobic styrenic resin) The kit is lodged in the Bellco "Lynda" machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter.

Sponsors & Collaborators

  • Bellco Srl Mirandola, Italy

    collaborator INDUSTRY

  • Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva

    lead OTHER

Principal Investigators

  • Sergio Livigni, MD · Ospedale San Giovanni Bosco, Torino, ITALY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-12-31
Completion
2011-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332371 on ClinicalTrials.gov